{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:40:45Z","timestamp":1679028045175},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1671","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Mosunetuzumab-axgb (Lunsumio \u2013 Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for treatment of relapsed or refractory follicular lymphoma in adults who received \u22652 lines of systemic therapy. It is the first T-cell-engaging bispecific antibody to be approved in the US for this indication.<\/jats:p>","DOI":"10.58347\/tml.2023.1671f","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:45:06Z","timestamp":1678981506000},"page":"e41-e42","source":"Crossref","is-referenced-by-count":0,"title":["Mosunetuzumab (Lunsumio) for Follicular Lymphoma"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,3,6]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:45:06Z","timestamp":1678981506000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1671f"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":0,"journal-issue":{"issue":"1671","published-online":{"date-parts":[[2023,3,6]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1671f","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}